返老还童
医学
面部修复
软组织
美容技术
抗逆转录病毒疗法
鼻唇沟
皱纹
脂肪营养不良
人类免疫缺陷病毒(HIV)
脂肪萎缩
透明质酸
外科
皮肤病科
病毒载量
解剖
家庭医学
老年学
作者
Ahmad Jabbar,Suleima Arruda,Neil S. Sadick
出处
期刊:PubMed
日期:2017-05-01
卷期号:16 (5): 489-494
被引量:37
摘要
Injectable soft-tissue augmentation agents have become popular alternatives to surgical procedures for the aging face and body. In contrast to temporary, space-occupying replacement fillers such as collagen-based and hyaluronic acid products, poly-l-lactic acid (PLLA) has been demonstrated to gradually promotes deposition of collagen via a biostimulatory response, with therapeutic effects lasting approximately two years. In 2004, the FDA approved its use for rejuvenation of facial contours secondary to lipoatrophy associated with antiretroviral therapy for HIV infection. By 2009 PLLA was FDA-approved for the correction of nasolabial fold contour deficiencies and other lines and wrinkles. There have since been limited but promising results with off-label use of PLLA for nonfacial volumization as well, including the hands, neck/décolleté, abdomen, and gluteal area. The objective of this article is to review clinical evidence, current trends, and technical considerations for the use of PLLA for nonfacial, body rejuvenation. J Drugs Dermatol. 2017;16(5):489-494. .
科研通智能强力驱动
Strongly Powered by AbleSci AI